Lilly and Hims & Hers Expand Self-Pay Access to Zepbound and Foundayo

Eli Lilly and Company and Hims & Hers Health, Inc. announced an agreement on November 6 to help expand access to two of Lilly's FDA-approved medicines, Zepbound (tirzepatide) and Foundayo (orforglipron), through the Hims & Hers telehealth platform, according to a joint announcement carried on markets.ft.com and republished in a Hims & Hers newsroom release.

What the Agreement Covers

Under the arrangement, eligible patients who receive a prescription from a licensed provider on the Hims & Hers platform will access the same self-pay prices available to any patient, without leaving the platform, the companies said. Self-pay pricing starts at $149 per month for Foundayo and $299 per month for Zepbound, according to the announcement. Comparing those two published figures, Foundayo's starting self-pay price is $150 below Zepbound's, or about 50% lower (calculation: (149 − 299) ÷ 299 × 100 = −50.2%). That gap reflects the two separately disclosed starting price points; the companies did not describe any discount structure behind either figure.

Lilly executive Ilya Yuffa said the deal is about "meeting patients where they already are," adding that millions of people who already turn to Hims & Hers for care now have "a simple, more direct way to get FDA-approved Lilly medicine at an affordable price if prescribed," per the companies' statement. Hims & Hers chief executive Andrew Dudum said he was "incredibly proud" that his company is "part of making sure more people can access" Lilly's medicines, calling Lilly "one of the most innovative pharmaceutical companies in history," according to the same release.

Compounding Restrictions and Clinical Independence

The announcement specifies that Hims & Hers "has never offered access to compounded copies of Lilly's GLP-1s" and has committed not to do so going forward. The companies also said they have committed to "protecting independent clinical decision-making," so that providers on the Hims & Hers platform continue to prescribe whatever treatment they determine is appropriate for each patient. Beyond those two specific commitments, no exclusivity terms, contract duration, or sales and volume targets were disclosed in the companies' statement.

How It Compares With the Novo Nordisk Deal

How It Compares With the Novo Nordisk Deal

The Lilly-Hims & Hers agreement also arrives alongside other recent Lilly moves to broaden access to its obesity portfolio. In November 2025, Lilly and the U.S. government announced an agreement aimed at expanding access to obesity medicines for millions of Americans, according to a PR Newswire release. In September 2026, Lilly launched the "Change the Course Commitment," aimed at addressing treatment gaps in diabetes and obesity in low- and middle-income countries, per a separate PR Newswire announcement. Read together, these announcements suggest — as interpretation rather than a company statement — a pattern of Lilly pursuing access-expansion agreements across multiple channels and geographies. The available materials do not describe how the Hims & Hers arrangement fits alongside Lilly's other distribution channels.

Market Context

The companies' announcement did not disclose financial terms beyond the published self-pay prices, and the available reporting contains no market-reaction data tied to the news. For broader context on Lilly's standing in the obesity market, IQVIA reported in a January 2026 outlook on the obesity drug market that Eli Lilly had become the first pharmaceutical company to surpass a $1 trillion market capitalization, a milestone IQVIA attributed to global demand for obesity medications. That figure predates the November 6 announcement and should not be read as a reaction to this specific deal.

Bottom Line

The agreement gives eligible Hims & Hers patients a self-pay path to two named Lilly medicines, Zepbound and Foundayo, at disclosed starting prices of $299 and $149 per month respectively, without requiring patients to leave the platform. The companies paired that expanded access with a commitment that Hims & Hers will not offer compounded copies of Lilly's GLP-1s and with a commitment to independent clinical prescribing — terms that echo, without matching, the compounding provisions BioPharma Dive reported in the earlier Novo Nordisk arrangement. What remains undisclosed, including exclusivity, contract length, and volume commitments, limits how fully the deal's commercial scale can be assessed from the public record alone.